Answers are grounded in this paper and cite their sources.
Aggregation and accumulation of amyloid β and tau proteins to plaques and neurofibrillary tangles are the key pathogenic events in Alzheimer's disease. Here, we studied the capability of the cyclic d,l-α-peptide CP-2 as a conformational inhibitor of different amyloids to cross-interact with tau-derived AcPHF6 peptide and inhibit its aggregation, membrane perturbation and toxicity.
No takes yet. Share an insight, caveat, or question.
Belostozky et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: